co-founder and chief medical officer of BioNTech. "We must not forget that cancer is also a global health threat, even worse than the current pandemic," she added.

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...

Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer/ BioNTech win U.K. nod for JN.1-adjusted COVID-19 ...

BioNTech has announced the initiation of global clinical trials for BNT116, an mRNA vaccine for the potential treatment of non-small cell lung cancer (NSCLC). The vaccine is claimed to use the ...

Update on Phase 3 Pfizer and BioNTech Combination Vaccine Trial ... match for the next season’s vaccine is difficult for global health experts as those strains are chosen more than six months ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

German vaccine manufacturer BioNTech is to sponsor Bundesliga side Mainz, the club announced on Friday. Mainz said the ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

"BioNTech"), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Tempus' robust multimodal datasets in ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...